A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma
Clinical Trial Grant
Awarded By
Oncternal Therapeutics, Inc.
Start Date
March 7, 2018
End Date
September 16, 2022
Awarded By
Oncternal Therapeutics, Inc.
Start Date
March 7, 2018
End Date
September 16, 2022